SML3961

Paricalcitol

≥98% (HPLC)

• Synonyme(s) : (1R,3R)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)cyclohexane-1,3-diol, (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol, 19-Nor-1alpha,25-dihydroxyvitamin D2
• Formule empirique (notation de Hill): C₂₇H₄₄O₃
• Numéro CAS: 131918-61-1
• Poids moléculaire : 416.64
• Code UNSPSC : 12352200

Propriétés

• Niveau de qualité: 100
• Pureté: ≥98% (HPLC)
• Forme: powder
• Couleur: white to beige
• Solubilité: DMSO: 2 mg/mL, clear
• Température de stockage: -10 to -25°C

Description

Actions biochimiques/physiologiques

Agonist for the calcitriol (Vitamin D receptor); Vitamin D analog; Antihyperparathyroid.

Paricalcitol is Vitamin D analog that acts as an agonist for the calcitriol receptor (Vitamin D receptor, VDR). It suppresses parathyroid hormone (PTH) gene transcription and PTH secretion and has been used clinically because of its antihyperparathyroid activity without inducing hypercalcemia or hyperphosphatemia. There is growing evidence that vitamin D either directly or indirectly affects cardiac structure and function. Paricalcitol showed improvement of cardiac function after myocardial infarction in mice with decreases in biomarkers, apoptosis, inflammation, and fibrosis.